OQROGet OQRO Pro
Insider trade

Eli Lilly (LLY)Officer sold ~$294K

Daniel Skovronsky, Officer at Eli Lilly, sold ~$294K of Eli Lilly shares.

~$294K
Approx. value · 340 sh @ $863.97
119K
Holds after · shares reported
Traded
Feb 10, 2025
Filed
Feb 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 8, 2024CongressDisclosed sale of LLY — reported range $15,001 - $50,000
  2. Dec 9, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  3. Dec 10, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  4. Dec 11, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  5. Dec 12, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  6. Dec 13, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  7. Dec 16, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  8. Dec 18, 2024CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  9. Dec 20, 2024FDAFDA drug approval: Zepbound
  10. Dec 24, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  11. Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  12. Jan 15, 2025FDAFDA drug approval: Omvoh
  13. Jan 15, 2025FDAFDA drug approval: Omvoh
  14. Jan 21, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  15. Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
  16. Jan 27, 2025FDAFDA drug approval: Cyramza
  17. Feb 6, 2025Insider · 1 personInsiders: 22 sales (~$183.6M)
  18. Feb 10, 2025 · this disclosureInsiderOfficer sold ~$294K of LLY shares in the open market

What came next

  1. Feb 10, 2025Insider · 1 personInsiders: 2 sales (~$4.0M)
  2. Feb 10, 2025CongressDisclosed sale of LLY — reported range $50,001 - $100,000
  3. Feb 13, 2025Insider · 1 personInsiders: 7 sales (~$31.2M)
  4. Feb 19, 2025Insider · 1 personInsiders: 4 sales (~$8.8M)
  5. Feb 20, 2025Insider · 1 personInsiders: 4 sales (~$12.9M)
  6. Feb 21, 2025Insider · 1 personInsiders: 17 sales (~$87.8M)
  7. Feb 24, 2025Insider · 1 personInsiders: 10 sales (~$30.7M)
  8. Apr 7, 2025FDAFDA drug approval: Cyramza
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Daniel Skovronsky, EVP, CSO & Pres. LRL & LLY Imm

The full history of Daniel Skovronsky, EVP, CSO & Pres. LRL & LLY Imm is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data